These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8869018)

  • 21. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Narins CR; Miller DP; Califf RM; Topol EJ
    J Am Coll Cardiol; 1999 Mar; 33(3):647-53. PubMed ID: 10080464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ; Califf RM; Aguirre FV; Anderson K; Sigmon KN; Weisman HF; Topol EJ
    Am J Cardiol; 1995 Mar; 75(8):559-62. PubMed ID: 7887377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of abciximab for patients undergoing balloon angioplasty: data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT).
    Nakagawa Y; Nobuyoshi M; Yamaguchi T; Meguro T; Yokoi H; Kimura T; Hosoda S; Kanmatsuse K; Matsumori A; Sasayama S
    Circ J; 2009 Jan; 73(1):145-51. PubMed ID: 19023152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators.
    Thel MC; Califf RM; Tcheng JE; Sigmon KN; Lincoff AM; Topol EJ; Ellis SG
    Am Heart J; 1999 Feb; 137(2):264-73. PubMed ID: 9924160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
    Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS
    J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Blockade.
    Ellis SG; Lincoff AM; Miller D; Tcheng JE; Kleiman NS; Kereiakes D; Califf R; Topol EJ
    J Am Coll Cardiol; 1998 Nov; 32(6):1619-23. PubMed ID: 9822087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty.
    Wöhrle J; Grebe OC; Nusser T; Al-Khayer E; Schaible S; Kochs M; Hombach V; Höher M
    Circulation; 2003 Apr; 107(14):1840-3. PubMed ID: 12682003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS; Tamhane U; Meier P; Grossman PM; Chetcuti S; Bates ER
    Circ Cardiovasc Interv; 2009 Jun; 2(3):230-6. PubMed ID: 20031720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of coronary angiograms prior to and after treatment with abciximab, and the outcome of angioplasty in refractory unstable angina patients. Angiographic results from the CAPTURE trial.
    van den Brand M; Laarman GJ; Steg PG; De Scheerder I; Heyndrickx G; Beatt K; Kootstra J; Simoons ML
    Eur Heart J; 1999 Nov; 20(21):1572-8. PubMed ID: 10529325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical safety using the thrombocyte aggregation inhibitor c7E3 in interventional cardiology in 520 patients].
    Machnig T; Zahn R; Rustige J; Gödicke J; Marsalek P; Gulba D
    Z Kardiol; 1997 Dec; 86(12):975-81. PubMed ID: 9499495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
    van den Brand MJ; Simoons ML; de Boer MJ; van Miltenburg A; van der Wieken LR; de Feyter PJ
    Eur Heart J; 1995 Nov; 16 Suppl L():36-42. PubMed ID: 8869017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation.
    Dunn CJ; Foster RH
    Pharmacoeconomics; 1999 Dec; 16(6):711-41. PubMed ID: 10724797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
    Klootwijk P; Meij S; Melkert R; Lenderink T; Simoons ML
    Circulation; 1998 Oct; 98(14):1358-64. PubMed ID: 9760288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Abciximab. An updated review of its use in ischaemic heart disease.
    Foster RH; Wiseman LR
    Drugs; 1998 Oct; 56(4):629-65. PubMed ID: 9806109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.